January 15, 2026 2:22 pm

Latest Posts

AI Partnership Brings New Hope for Personalized IBD Treatment

AstraZeneca and AI partner Immunai have committed up to $85 million to develop personalized IBD treatments using artificial intelligence. This partnership could eventually help doctors predict which treatments will work best for each patient’s unique biology, potentially ending the current trial-and-error approach to IBD care.

New Hope for Pediatric IBD: Global Coalition Takes Action

The Critical Path Institute has launched DIMENSION, a global coalition focused specifically on accelerating pediatric IBD treatment development through advanced modeling techniques. This international collaboration promises new hope for children and families affected by Crohn’s disease and ulcerative colitis.

Biofilm Research Breakthrough: New Hope for IBD Treatment

Groundbreaking research into bacterial biofilms could unlock new treatment strategies for IBD patients. Dr. Ilana Kolodkin-Gal’s prestigious grant-funded work in synthetic biology aims to understand how bacteria form resistant communities, potentially leading to more effective therapies for managing IBD-related infections and inflammation.

You Missed

Breakthrough Rapid Test Could Transform IBD Diagnosis: What This Means for Patients

Breakthrough Rapid Test Could Transform IBD Diagnosis: What This Means for Patients

January 13, 2026
Navigating IBD Medication Shortages: Your Emergency Action Plan

Navigating IBD Medication Shortages: Your Emergency Action Plan

January 12, 2026
Total Abdominal Colectomy Shows Promise for Ulcerative Colitis: What This Means for Your Treatment Journey

Total Abdominal Colectomy Shows Promise for Ulcerative Colitis: What This Means for Your Treatment Journey

January 12, 2026
This Week in IBD: Your Weekly Roundup for January 5-11, 2026

This Week in IBD: Your Weekly Roundup for January 5-11, 2026

January 11, 2026